Oculis Holding AG (FRA:CR5) Additional Paid-In Capital : €298.58 Mil(As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Additional Paid-In Capital?

Oculis Holding AG's quarterly additional paid-in capital increased from Sep. 2023 (€300.01 Mil) to Dec. 2023 (€305.56 Mil) but then stayed the same from Dec. 2023 (€305.56 Mil) to Mar. 2024 (€298.58 Mil).

Oculis Holding AG's annual additional paid-in capital increased from Dec. 2021 (€10.03 Mil) to Dec. 2022 (€10.89 Mil) and increased from Dec. 2022 (€10.89 Mil) to Dec. 2023 (€305.56 Mil).

Oculis Holding AG Additional Paid-In Capital Historical Data

The historical data trend for Oculis Holding AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Additional Paid-In Capital Chart

Oculis Holding AG Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

8.89

10.03

10.89

305.56

Oculis Holding AG Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial							-	293.89	300.01	305.56	298.58

Oculis Holding AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Oculis Holding AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Oculis Holding AG (FRA:CR5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

OCS:USA OCS:Iceland

Address

Bahnhofstrasse 7, Zug, CHE, 6300

Website

https://www.oculis.com

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines